In contrast, different studies indicated that Sorafenib induced an inhibition of STAT3 (phosphorylated signaltransducers and activators of transcription 3) that were associated with decreased levels of pAkt in glioblastoma cells, pancreatic cancer cell lines and neuroblastoma cells [16,21,22]. The gene discussed is STAT3; the disease is glioblastoma.